Our outpatient clinic at Alfried Krupp Krankenhaus, Essen, provides diagnosis and multidisciplinary care to around 500 patients with ALS and related motoneuron diseases. Our clinical research currently focuses on managed care, shared decison making (SDM) and palliative care. The ALS outpatient clinic cooperates with the ALS management platform AmbulanzPartner (www.ambulanzpartner.de).
| Alfried Krupp Krankenhaus, ALS outpatient clinic | |
|---|---|
| Foundation year | 2016 |
| Director | Prof. Dr. med. Peter Berlit |
| Principal investigator | Dr. med. Torsten Grehl |
| Contact information | |
|---|---|
| Address | Alfried-Krupp-Straße 21 |
| Contact | Dr. med. Torsten Grehl |
| Phone | +49(0)201-4342913 |
| Fax | +49(0)201-4342377 |
| torsten.grehl@rub.de | |
| Website | Visit the website |
Publications
- Dorst, J., et al. (2015). “Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study.” J Neurol 262(4): 849-858.
- Gerardo-Nava, J., et al. (2014). “Spinal cord organotypic slice cultures for the study of regenerating motor axon interactions with 3D scaffolds.” Biomaterials 35(14): 4288-4296.
- Grehl, T. (2013). “[Diagnostics and therapy for amyotrophic lateral sclerosis].” Fortschr Neurol Psychiatr 81(10): 592-603;
- Gerardo-Nava, J., et al. (2013). “Differential pattern of neuroprotection in lumbar, cervical and thoracic spinal cord segments in an organotypic rat model of glutamate-induced excitotoxicity.” J Chem Neuroanat 53: 11-17.
- Synofzik, M., et al. (2012). “Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype.” Neurobiol Aging 33(12): 2949 e2913-2947.
Restricted information
| Serving population | |
|---|---|
| Serving population | 1.000.0000 or more |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | No |
| Number of skin samples | 80 |
| Number of IPS cell samples | 5 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | 370 | 100 | 0 |
| Serum Bank | 370 | 100 | 50 |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | Yes |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | No |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| RAS-ALS , 2013, Eudra CT 2011-004482-32 | RAS-ALS , 2013, Eudra CT 2011-004482-32 | 10 |
| NOG112264; Eudra CT 2012-003349-13 | NOG112264; Eudra CT 2012-003349-13 | 10 |
| ENVISION 2012; Eudra CT 2011-006119-70 | ENVISION 2012; Eudra CT 2011-006119-70 | 20 |
| EMPOWER 2011; Eudra CT 2010-022818-19 | EMPOWER 2011; Eudra CT 2010-022818-19 | 20 |
| ALS-TAL201 2009; Eudra CT 2008-002062-62 | ALS-TAL201 2009; Eudra CT 2008-002062-62 | 20 |
| SIRONA 2007; Eudra CT 2007-004723-37 | SIRONA 2007; Eudra CT 2007-004723-37 | 18 |
| ALS-GA-201 2006; Eudra CT 2006-00168-49 | ALS-GA-201 2006; Eudra CT 2006-00168-49 | 22 |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| LIPCAL-ALS, NCT02306590, high calorie dietary | LIPCAL-ALS, NCT02306590, high calorie dietary | 15 |
| GERP 2009; Eudra CT 2006-005410-13 | GERP 2009; Eudra CT 2006-005410-13 | 15 |